A hazard ratio of 0.36 for progression-free survival is not a modest improvement over chemotherapy — it is a near-dismantling of the comparator arm. The RC48-C016 trial, which drove China’s NMPA approval of toripalimab plus disitamab vedotin for first-line HER2-expressing urothelial carcinoma, produced a median PFS of 13.1 months against 6.5 months for gemcitabine-based chemotherapy, and an OS of 31.5 months against 16.9 months. Both primary endpoints were hit, both with p-values well below 0.0001. The magnitude here matters: a doubling of PFS and near-doubling of OS in a tumor type where systemic options have historically offered limited durability is a qualitative shift in what first-line treatment can achieve.
The design of RC48-C016 deserves scrutiny because it makes the result both more impressive and more precise in scope. The trial enrolled systemic-treatment-naive patients across 74 Chinese centers, defined HER2 expression broadly — IHC 1+, 2+, or 3+ — and randomized against platinum-based chemotherapy. That broad HER2 definition is clinically significant: it captures a substantially larger patient population than HER2-positive thresholds used in breast or gastric cancer trials, and it means the efficacy signal extends well beyond the high-expressors. An ORR of 76.1% versus 50.2%, with duration of response nearly tripling to 14.6 months, reinforces that this is not a response-rate story that collapses at follow-up.
The combination itself represents a structurally distinct mechanism pairing. Disitamab vedotin is a HER2-directed antibody-drug conjugate that delivers cytotoxic payload directly to tumor cells; toripalimab blocks PD-1 and, notably, promotes receptor internalization — a mechanistic feature that may enhance T-cell reactivation beyond simple checkpoint blockade. Whether that internalization property contributes meaningfully to the synergy seen here remains an open question, but the preclinical rationale is not trivial. The trial’s publication in NEJM and its Presidential Symposium slot at ESMO 2025 signal that the oncology community treated the data as practice-informing, not merely confirmatory.
The approval is China-specific for now, but the dataset is robust enough to anchor global regulatory conversations. The single marker to track: whether RemeGen and Junshi pursue an FDA submission for disitamab vedotin plus toripalimab in urothelial carcinoma, and whether the broad IHC 1+ threshold survives Western regulatory scrutiny as the defining eligibility criterion.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
